Lotiglipron

Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer. It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.